Nanoparticles as novel carrier for brain delivery: A review

Current Pharmaceutical Design

Volumn 15, Issue 8, 2009, Pages 917-925

  Agarwal, Abhinav ^a   Lariya, Narendra ^a   Saraogi, Gauravkant ^a   Dubey, Nidhi ^a   Agrawal, Himanshu ^b   Agrawal, G P ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

Adsorption; Blood brain barrier; Drug delivery; Endocytosis; Nanoparticles; P glycoprotein efflux pump

Indexed keywords

ALGINIC ACID; CAMPTOTHECIN; CARMUSTINE; CELL PENETRATING PEPTIDE; CHITOSAN; DAUNORUBICIN; DELAVIRDINE; DOXORUBICIN; GLYCOPROTEIN P; IMMUNOLIPOSOME; LACTIC ACID; LIPOSOME; MALTODEXTRIN; METHOTREXATE; MICROSPHERE; NANOPARTICLE; POLOXAMER; POLY(METHYL METHACRYLATE); POLYOXYETHYLENE OLEYL ETHER; POLYSORBATE 80; SAQUINAVIR; SEBACIC ACID; SOLID LIPID NANOPARTICLE; STAVUDINE; SURFACTANT; TRANSFERRIN RECEPTOR; TUBOCURARINE CHLORIDE; ULEX EUROPAEUS AGGLUTININ; UNINDEXED DRUG; WHEAT GERM AGGLUTININ;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BRAIN EDEMA; CANCER SURVIVAL; CELL DISRUPTION; CLINICAL TRIAL; COCULTURE; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; GLIOBLASTOMA; HUMAN; HYDROCEPHALUS; INFECTION; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MEMBRANE PERMEABILITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SURVIVAL TIME; TRANSCYTOSIS;

ADSORPTION; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM AGENTS; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; NANOPARTICLES;

EID: 65649149025     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582057     Document Type: Review

References (72)

1. Pardridge WM. Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 2003; 3: 90-05.
2. Kreuter J. Nanoparticles. In: Kreuter J, Ed. Colloidal Drug Delivey Systtems. Marcel Dekker: New York 1994; 219-42.
3. Ringe K, Walz CM, Sabel BA. In: Nalwa HS, Ed. Nanoparticle Drug Delivery to the Brain. Encyclopedia of Nanoscience and Nanotechnology: 2004; 7: 91-04.
4. Kaur A, Jain S, Tiwary AK. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation. Acta Pharm 2008; 58: 61-74.
5. Troster SD, Muller U, Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm 1990; 61: 85-00.
6. Thole M, Nobmanna S, Huwyler J, Bartmann A, Fricker G. Uptake of cationzied albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J Drug Target 2002; 10: 337-44.
7. Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 2002; 6(1): 67-72.
8. Podlecki DA, Smith RM, Kao M, Tsai P, Huecksteadt T, Brandenburg D, et al. Nuclear translocation of the insulin receptor. A possible mediator of insulin's long term effects. J Biol Chem 1987; 262(7): 3362-8.
9. Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. J Control Release 2007; 117: 51-8.
10. Huwyler J, Yang J, Pardridge WM. Targeted delivery of daunomycin using immunoliposomes: Pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther 1997; 282: 1541-6.
11. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93: 14164-9.
12. Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, et al. Expression of lactoferrin receptors in increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 1995; 92: 9603-7.
13. Pardridge WM. Receptor-mediated peptide transport through the blood-brain barrier. Endocrine Rev 1986; 7: 314-30.
14. Brown JP, Hewick RH, Hellstrom I, Hellstrom KE, Doolittle RF, Dreyer WJ. Human melanotransferrin antigen p97 is structurally and functionally related to transferring. Nature (Lond) 1982; 296: 171-3.
15. Lu W, Tan YZ, Hu KL, Jiang XG. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier (Pharmaceutical Nanotechnology). Int J Pharm 2005; 295: 247-60.
16. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967; 34(1): 207-17.
17. Bickel U, Kang YS, Yoshikawa T, Pardridge WM. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem 1994; 42(11): 1493-7.
18. Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta Biomembr 1995; 1234(1): 74-80.
19. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999; 36: 179-94.
20. Tsuji A, Tamai I. Blood-brain barrier function of P-glycoprotein. Adv Drug Deliv Rev 1997; 25: 287-98.
21. Miller DW, Kabanov AV. Potential applications of polymers in the delivery of drugs to the central nervous system. Colloids Surfaces B: Biointerfaces 1999; 16: 321-30.
22. Koziara JM, Lockman PR, Allen DD, Mumper RJ. In situ blood-brain barrier transport of nanoparticles. Pharm Res 2003; 20: 1772-8.
23. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Rel 2004; 99: 259-69.
24. Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ, et al. In vivo and in vitro assessment of baseline bloodbrain barrier parameters in the presence of novel nanoparticles. Pharm Res 2003; 20: 705-13.
25. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: A review. J Pharm Pharmaceut Sci 2003; 6(2): 252-73.
26. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, Noel JP, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001; 18(8): 1157-66.
27. van der Sandt IC J, Gaillard PJ, Voorwinden HH, de Boer Douwe AG, Breimer D. P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. Pharm Res 2001; 18(5): 587-92.
28. DiMeco F, Li KW, Tyler BM, Wolf AS, Brem H, Olivi A. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 2002; 97(5): 1173-8.
29. Storm PB, Moriarity JL, Tyler B, Burger PC, Brem H, Weingart J. Polymer delivery of camptothecin against 9L gliosarcoma: Release, distribution, and efficacy. J Neuro Oncol 2002; 56(3): 209-17.
30. Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 2005; 25(6B): 3825-31.
31. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol 2003; 5(2): 79-88.
32. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148(3): 269-75.
33. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 1995; 345 (8956): 1008-12.
34. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Rel 1999; 59: 299-07.
35. Ji B, Maeda J, Higuchi M, Inoue K, Akita H, Harashima H, et al. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 2006; 78: 851-5.
36. Frank HJ, Pardridge WM. A direct in vitro demonstration of insulin binding to isolated brain microvessels. Diabetes 1981; 30(9): 757-61
37. Houten VM, Posner BI. Insulin binds to brain blood vessels in vivo. Nature 1979; 282(5739): 623-5.
38. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor. J Neurochem 1985; 44(6): 1771-8.
39. Duffy KR, Pardridge WM. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987; 420(1): 32-8.
40. Lockmana PR, Oyewumib MO, Koziarab JM, Rodera KE, Mumperb RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J Control Rel 2003; 93:271-82.
41. Tsutsui Y, Tomizawa K, Nagita M, Michiue H, Nishiki T, Ohmori I, et al. Development of bionanocapsules targeting brain tumors. J Control Release 2007; 122(2): 159-64.
42. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, et al. Direct evidence that polysorbate-80-coated poly(butyl cyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20: 409-16.
43. Alyautdin RN, Tezikov EB, Ramges P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polyisobutylcyanoacrylate nanoparticles: An in situ brain perfusion study. J Microencapsul 1998; 15: 67-74.
44. Chung NS, Wasan KM. Potential role of the low density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev 2004; 56: 1315-34.
45. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J Cell Biol 1997; 138: 877-89.
46. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles, Pharmaceutical Nanotechnology vitro Int J Pharm 2006; 310: 213-19.
47. Fischer D, Kissel T. Histochemical characterization of primary capillary endothelial cells from porcine brains using monoclonal antibodies and fluorescein isothiocyanate-labelled lectins: Implications for drug delivery. Eur J Pharm Biopharm 2001; 52(1): 1-11.
48. Ratcheson RA, Ommaya AK. Experience with the subcutaneous cerebrospinal-fluid reservoir. Preliminary report of 60 cases. N Engl J Med 1968; 279(19): 1025-31.
49. Pardridge WM. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm Sci Technol Today 1999; 2(2): 49-59.
50. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK, Vyas SP. Anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm 2003; 261: 43-55.
51. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2005; 2(1): 54-62.
52. Umezawa F, Eto Y. Liposome targeting to mouse brain: Mannose as a recognition marker. Biochem Biophys Res Commun 1988; 153(3): 1038-44
53. Kang YS, Terasaki T, Onishi T, Tsuji A. In vivo and in vitro evidence for a common carrier mediated transport of choline and basic drugs through the blood-brain barrier. J Pharmacobiol Dyn 1990; 13: 53.
54. Shimon M, Egozi Y, Kloong Y, Sokolovski M, Cohen S. Kinetics of choline uptake into isolated rat forebrain microvessels: Evidence of endocrine modulation. J Neurochem 1988; 50: 1719.
55. Fenart L, Casanova A, Dehouck B, Duhem C, Slupek S, Cecchelli R, et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 1999; 291(3): 1017-22.
56. Terasaki T, Täkakuwa S, Moritani S, Tsuji A. Transport of monocarboxylic acids at the blood-brain barrier: Studies with monolayers of primary cultured bovine brain capillary endothelial cells. J Pharmacol Exp Ther 1991; 258: 32.
57. Takanaga H, Thmai I, Inabe S, Sai Y, Higashiga H, Yamamoto H, et al. cDNA cloning and functional characterization of rat intestinal monocarboxylate transporter. Biochem Biophys Res Commun 1995; 217: 370.
58. Triguero D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G: Enhanced delivery compared to native protein. Proc Natl Acad Sci USA 1989; 86(12): 4761-5.
59. Pardridge WM, Triguero D, Buciak J, Yang J. Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. J Pharmacol Exp Ther 1990; 255(2): 893-99.
60. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, character-ization, radiolabeling, and biodistribution studies. AAPS J 2004; 6 (3): 1-10.
61. Jallouli Y, Paillard A, Chang J, Sevin E, Betbeder D. Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int J Pharm 2007; 344: 103-9.
62. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005; 107: 215-28
63. Chertok B, Moffat BA, David AE, Yu F, Bergemann C, Ross BD, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008; 29(4): 487-96
64. Jia W, Xu G, Sclabassi RJ, Zhu JG, Bagic A, Sun M. Detection of magnetic nanoparticles with magnetoencephalography, J Magnetism Magnetic Mater 2008; 320(8): 1472-8.
65. Gould P. Nanomagnetism shows in vivo potential. Nano Today 2006; 1(4): 34-39.
66. Mykhaylyk O, Cherchenko A, Ilkin A, Dudchenko N, Ruditsa V, Novoseletz M, et al. Glial brain tumor targeting of magnetite nanoparticles in rats. J Magnetism Magnetic Mater 2001; 225(1-2): 241-7.
67. Gao X, Chen J, Tao W, Zhu J, Zhang Q, Chen H, et al. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int J Pharm 2007; 340(1-2): 207-15.
68. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997; 14(10): 1431-36.
69. Major M, Prieur E, Tocanne JF, Betbeder D, Sautereau AM. Characterisation and phase behaviour of phospholipid bilayers adsorbed on spherical polysaccharidic nanoparticles. Biochim Biophys Acta Biomembr 1997; 1327(1): 32-40.
70. Diederichs JE, Vauthier C, Alphandary H, Couvreur P, Muller RH. Formation process and determination of microviscosity of alginate nanoparticles. Proc Control Release Soc 1994; 21: 511-12.
71. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998; 15(9): 1326-31.
72. Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropyl-methacrylate, and solid lipid nanoparticles (Pharmaceutical Nanotechnology). Int J Pharm 2007; 340: 143-52.